



Immune response



Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

Phases of adaptive immune response




Antigen uptake

Antigen processing

MHC biosynthesis

Peptide-MHC association




Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

Antigen uptake

Antigen processing


MHC biosynthesis

Peptide-MHC association




Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

Class I MHC






Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

Class II MHC



Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.



Antigen Presenting Cells

Dendritic cells:

- constitutive MHC II; Increase with INF γ
- Co-stimulatory molecules are constitutively expressed and inducible

Macrophages:

- constitutive MHC II; Increase with INF γ
- co-stimulatory molecules are inducible by LPS

B Lymphocytes:


- constitutive MHC II; Increase with IL4
- co-stimulatory molecules are inducible by T lymphocytes interaction (CD40-CD40L)

Vascular endothelial cells:

- constitutive MHC II; Increase with INF γ
- Co-stimulatory molecules are constitutively expressed


Epithelial and mesenchymal cells:

- constitutive MHC II; Increase with INF γ
- Co-stimulatory molecules seem not to be expressed




Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

T-cell Receptor




(A) Ig




Feature	$\alpha\beta$ T cells	$\gamma\delta$ T cells
CD4 and CD8 phenotype	Major subsetting based on CD4 or CD8 expression	Predominantly CD4 ⁻ CD8 ⁻ (double-negative); murine intestinal IELs may be CD8 $\alpha\alpha$ ⁺
Antigen type and presentation	Peptide antigen in the grooves of MHC-I or -II; primary responses require antigen-presenting cell	Identification of TCR ligands incomplete; β_2 microglobulin independent; some subsets recognize MHC-Ib molecules
T helper functions	Predominantly CD4 ⁺ ; T helper 1 and 2 cytokine profiles	T helper 1 and 2 cytokine profiles
T cytotoxic functions	Predominantly CD8 ⁺ ; e.g., perforin/granzyme production, Fas ligand-mediated, NKG2D-mediated	Various subsets using the same mechanisms
T regulatory functions	Various T regulatory subsets including CD4 ⁺ CD25 ⁺ cells	Attributable to various subsets, including murine V γ 5 ⁺ DETCs and human V γ 1 ⁺ peripheral cells
TCR junctional diversity	Relatively vast	Relatively limited; especially limited for IEL populations

Abbreviations: DETC, dendritic epidermal T cell; IEL, intraepithelial lymphocyte; MHC, major histocompatibility complex.


Human TCR β chain locus (620 kb; chromosome 7)




Human TCR α , δ chain locus (1000 kb; chromosome 14)




Human TCR γ chain locus (200 kb; chromosome 7)



T-cell maturation




Stage of maturation	Stem cell	Pro-T	Pre-T	Double positive
Proliferation	Yes	Yes	Yes	No
Rag expression	No	No	Yes	Yes
TdT expression	No	Yes	No	No
TCR DNA, RNA	Unrecombined (germline) DNA	Unrecombined (germline) DNA	Recombined β chain gene [V(D)J-C]; β chain mRNA	Recombined β , α chain genes [V(D)J-C]; β and α chain mRNA
TCR expression	None	None	Pre-T receptor (β chain/pre-T α)	Membrane $\alpha\beta$ TCR
Surface markers	$c\text{-kit}^+$ CD44 $^+$ CD25 $^-$	$c\text{-kit}^+$ CD44 $^+$ CD25 $^+$	$c\text{-kit}^+$ CD44 $^-$ CD25 $^+$	CD4 $^+$ CD8 $^+$ TCR/CD3 $^{\text{lo}}$
Anatomic site	Bone marrow	Thymus		
Response to antigen	None	None	None	Positive and negative selection



Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.


Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.





Stage of maturation	Stem cell	Pro-T	Pre-T	Double positive	Single positive (immature T cell)	Naive mature T cell
Proliferation	Orange bar		Orange bar			
Rag expression			Orange bar	Orange bar		
TdT expression		Orange bar				
TCR DNA, RNA	Unrecombined (germline) DNA	Unrecombined (germline) DNA	Recombined β chain gene [V(D)J-C]; β chain mRNA	Recombined β , α chain genes [V(D)J-C]; β and α chain mRNA	Recombined β , α chain genes [V(D)J-C]; β and α chain mRNA	Recombined β , α chain genes [V(D)J-C]; β and α chain mRNA
TCR expression	None	None	Pre-T receptor (β chain/pre-T α)	Membrane $\alpha\beta$ TCR	Membrane $\alpha\beta$ TCR	Membrane $\alpha\beta$ TCR
Surface markers	$c-kit^+$ CD44 ⁺ CD25 ⁻	$c-kit^+$ CD44 ⁺ CD25 ⁺	$c-kit^+$ CD44 ⁻ CD25 ⁺	CD4 ⁺ CD8 ⁺ TCR/CD3 ^{lo}	CD4 ⁺ CD8 ⁻ or CD4 ⁻ CD8 ⁺ TCR/CD3 ^{hi}	CD4 ⁺ CD8 ⁻ or CD4 ⁻ CD8 ⁺ TCR/CD3 ^{hi}
Anatomic site	Bone marrow	Thymus				Periphery
Response to antigen	None	None	None	Positive and negative selection		Activation (proliferation and differentiation)


Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
 Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

Hypothesis of T-cell maturation












Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
 Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.





B


Surface molecules of T lymphocytes	Function	Ligand	
		Name	Expressed on
CD3	Signal transduction by TCR complex	None	
ζ	Signal transduction by TCR complex	None	
CD4	Signal transduction	Class II MHC	Antigen presenting cells
CD8	Signal transduction	Class I MHC	All nucleated cells
CD28	Signal transduction (costimulation)	B7-1/B7-2	Antigen presenting cells
CTLA-4	Inhibition	B7-1/B7-2	Antigen presenting cells
PD-1	Inhibition	PD-L1/PD-L2	Antigen presenting cells, tissue cells, tumor cells
LFA-1	Adhesion, signal transduction	ICAM-1	Antigen presenting cells, endothelium








Name	B7-1 (CD80)	B7-2 (CD86)	ICOS-L (CD275)	PD-L1 (B7-H1, CD274)	PD-L2 (B7-DC, CD273)
------	-------------	-------------	----------------	----------------------	----------------------






Name	CD28	CTLA-4	ICOS	PD-1
Major function	Activation (naive T cells)	Inhibition (mediates suppressive function of regulatory T cells)	Activation (follicular helper T cells in antibody responses)	Inhibition


Lymphocytes maturation



Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.











FIGURE 6-7 Development of Th1, Th2, and Th17 effector cells. Dendritic cells and other immune cells that respond to different types of microbes secrete cytokines that induce the development of antigen-activated CD4⁺ T cells into Th1 (A), Th2 (B), and Th17 (C) subsets. The transcription factors that are involved in T cell differentiation are indicated in boxes in the antigen-activated T cells.









FIGURE 6-3 Characteristics of subsets of CD4⁺ helper T lymphocytes. A naive CD4⁺ T cell may differentiate into subsets that produce different cytokines that recruit and activate different cell types (referred to as *target cells*) and combat different types of infections in host defense. These subsets also are involved in various kinds of inflammatory diseases. The table summarizes the major differences among Th1, Th2, and Th17 subsets of helper T cells. *IFN*, Interferon; *IL*, interleukin.








B

T cell homing receptor	Ligand on endothelial cell	Function of receptor: ligand pair
Naive T cells L-selectin	L-selectin ligand	Initial weak adhesion of naive T cells to high endothelial venule (HEV) in lymph node
LFA-1 (β_2 -integrin)	ICAM-1	Stable arrest on HEV
CCR7	CCL19 or CCL21	Activation of integrins and chemotaxis
Activated (effector and memory) T cells E- and P-selectin ligand	E- or P-selectin	Initial weak adhesion of effector and memory T cells to cytokine-activated endothelium at peripheral site of infection
LFA-1 (β_2 -integrin) or VLA-4 (β_1 integrin)	ICAM-1 or VCAM-1	Stable arrest on cytokine-activated endothelium at peripheral site of infection
CXCR3, others	CXCL10, others	Activation of integrins and chemotaxis



Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
 Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.









FIGURE 6-12 Mechanisms of killing of infected cells by CD8⁺ cytotoxic T lymphocytes (CTLs). CTLs recognize class I MHC-associated peptides of cytoplasmic microbes in infected cells and form tight adhesions (conjugates) with these cells. Adhesion molecules such as integrins stabilize the binding of the CTLs to infected cells (not shown). The CTLs are activated to release (exocytose) their granule contents (perforin and granzymes) toward the infected cell, referred to as the target cell. Granzymes are delivered to the cytosol of the target cell by a perforin-dependent mechanism. Granzymes then induce apoptosis. *ICAM-1*, Intercellular adhesion molecule 1; *LFA-1*, leukocyte function-associated antigen 1.

How APC present tumor Ags???

Tumor antigens recognized by CTL

Normal host cell displaying multiple MHC-associated self antigens	 <p>Normal self protein</p> <p>No T cell response</p>	Examples
	 <p>Mutated self protein</p>	<p>Various mutant proteins in carcinogen or radiation induced animal tumors; various mutated proteins in melanomas</p>
Tumor cells expressing different types of tumor antigens	 <p>Product of oncogene or mutated tumor suppressor gene</p> <p>CD8⁺ CTL</p>	<p>Oncogene products: mutated Ras, Bcr/Abl fusion proteins Tumor suppressor gene products: mutated p53 protein</p>
	 <p>Overexpressed or aberrantly expressed self protein</p> <p>CD8⁺ CTL</p>	<p>Overexpressed: tyrosinase, gp100, MART in melanomas. Aberrantly expressed: Cancer/testis antigens (MAGE, BAGE)</p>
	 <p>Oncogenic virus</p> <p>Virus antigen-specific CD8⁺ CTL</p>	<p>Human papilloma virus E6, E7 proteins in cervical carcinoma; EBNA proteins in EBV-induced lymphomas</p>

Escape of immune response by cancer cells (tumor escape)

“Several data showed that tumors developed in immunodeficient mice were easily rejected with respect to tumors from WT mice, studying transplantation in WT mice.

It indicates that tumors developed in immune-sufficient mice generate less immunogenic tumor variants”

Abbas et al.
Molecular and cellular Immunology
6th edition

Escape of immune response by cancer cells (tumor escape) (1)

- Tumor Ags may induce specific immune tolerance


(in particular viral Ags)

Tumor escape (2)

- Tumor cells reduce the expression of tumor Ags


(particularly evident in tumor with very fast growth in which mut/del can be included in the sequence of TAA)

Anti-tumor immunity



Failure to produce tumor antigen


Antigen-loss variant of tumor cell




Lack of T cell recognition of tumor

Immune evasion by tumors

Induction of a T-response against tumor



Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.




Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

Tumor escape (3)


- Some tumor cells reduce the expression of MHC I

Anti-tumor immunity



Failure to produce tumor antigen

Antigen-loss variant of tumor cell




Immune evasion by tumors

Mutations in MHC genes or genes needed for antigen processing

Class I MHC-deficient tumor cell



Induction of a T-response against tumor




Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

Tumor escape (4)


- Several tumor cells do not express the ideal co-stimulatory molecules, avoiding a correct response of CTL

(moreover, tumor cells over-expressing CD80 or CD86 induce a strong cell-mediated immune response)



Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
 Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

Induction of a T-response against tumor




Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

Tumor escape (5)

- products secreted by tumor cells can inhibit effector T-cell response

(es. TGF- β secreted by tumor cells inhibit proliferation and functional activation of CD8⁺ T-lymphocytes)

Anti-tumor immunity



T cell recognition of tumor antigen leading to T cell activation

Failure to produce tumor antigen

Antigen-loss variant of tumor cell



Lack of T cell recognition of tumor

Immune evasion by tumors


Mutations in MHC genes or genes needed for antigen processing

Class I MHC-deficient tumor cell




Lack of T cell recognition of tumor

Production of immunosuppressive proteins



Inhibition of T cell activation

Induction of a T-response against tumor




Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.


Tumor escape (5)

- products secreted by tumor cells can inhibit effector T-cell response















(es. TGF- β secreted by tumor cells inhibit proliferation and functional activation of CD8⁺ T-lymphocytes)

... but also of macrophages
(APC but also part of the innate immunity)





B

Surface molecules of T lymphocytes	Function	Ligand	
		Name	Expressed on
CD3 	Signal transduction by TCR complex	None	
ζ 	Signal transduction by TCR complex	None	
CD4 	Signal transduction	Class II MHC 	Antigen presenting cells
CD8 	Signal transduction	Class I MHC 	All nucleated cells
CD28 	Signal transduction (costimulation)	B7-1/B7-2 	Antigen presenting cells
CTLA-4 	Inhibition	B7-1/B7-2 	Antigen presenting cells
PD-1 	Inhibition	PD-L1/PD-L2 	Antigen presenting cells, tissue cells, tumor cells
LFA-1 	Adhesion, signal transduction	ICAM-1 	Antigen presenting cells, endothelium





Escape of immune response by cancer cells (tumor escape) (6)

- Regulatory T lymphocytes inhibit T-cell response against cancer cells


(Studies in animal models or in patient' samples evidenced and increase number of Treg and their preferential localization in tumor microenvironment)

Classes of lymphocytes





Induction of a T-response against tumor



Abbas et al: Cellular and Molecular Immunology, Updated 6th Edition.
Copyright © 2009 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

Tumor escape (7)

- increased expression of membrane complement inhibitors on tumor cells

(over-expression of CD46, CD55 e CD59 neutralized the lytic activity of the complement system)

ALTERNATIVE PATHWAY

LECTIN PATHWAY

CLASSICAL PATHWAY

Activating surfaces

Carbohydrates


Immune complexes

C3b C3H₂O



MBL

C1q

C1Inh
C4BP



MASP
C4
C2



RECOGNITION


CD55

C3

FactorH
CD46



C3b



OPSONIZATION

C3a
C5a

INFLAMMATION

S-Protein
Clusterin
CD59


C5





C6C7

C8 C9

C5b-9

CYTOLYSIS
INFLAMMATION





Question:

Is it possible enhance immune response against tumor cells and avoid tumor escape?

Answer:

Cancer Immunotherapy